Cancer targeting complex, and composition comprising same for preventing or treating cancer

A cancer-targeting complex that binds to albumin and releases PROTAC within cancer cells addresses the limitations of existing anticancer drugs by enhancing bioavailability and specificity, achieving substantial anti-cancer effects while avoiding normal tissue toxicity.

WO2024237414A1PCT designated stage expired Publication Date: 2024-11-21EWHA UNIV IND COLLABORATION FOUND
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/020713
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-16
Filing Date
2023-12-15
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current anticancer drugs, such as PROTAC, face challenges with low efficacy due to their small molecular structure and hydrophobicity, leading to insufficient effectiveness in clinical practice, and nanomaterial-based carriers cause side effects, necessitating a new platform for targeted cancer therapy.

Method used

A cancer-targeting complex is developed that binds to albumin in vivo, forming a stabilized and inactivated state, which penetrates cancer cells and is cleaved by esterase to release PROTAC, specifically targeting proteins like BRD4, enhancing cancer treatment specificity and efficacy.

Benefits of technology

The cancer-targeting complex achieves significant anti-cancer effects by deep penetration into cancer tissues, reducing proliferation by 5 to 6 times compared to PROTAC alone, with no toxicity to normal cells, and demonstrates improved bioavailability and targeting accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023020713_21112024_PF_FP_ABST
    Figure KR2023020713_21112024_PF_FP_ABST
Patent Text Reader

Abstract

As a cancer targeting complex according to the present invention, immediately binds to albumin, when administered in vivo, and exists in a stable and inactive state, the cancer targeting complex may provide enhanced cancer treatment, prevention, and amelioration effects specific to cancer tissue without exhibiting toxicity to normal tissue.
Need to check novelty before this filing date? Find Prior Art

Description

Cancer targeting complex, composition for preventing or treating cancer comprising the same

[0001] The present invention relates to a cancer-targeting complex, and more specifically, to a complex that targets cancer and is efficiently absorbed by cancer cells to effectively prevent or treat cancer, and a composition for preventing, treating, or improving cancer comprising the complex.

[0002] According to statistics from the International Agency for Research on Cancer (IARC), a division of the World Health Organization (WHO), South Korea has the highest incidence of colorectal cancer in the world. Due to factors such as an aging population, obesity, and changing dietary habits, it ranks among the most common cancers among Koreans. Various chemotherapeutic agents, immunotherapies, and targeted therapies have been developed for cancer treatment. Targeted therapies are known to be highly effective in specifically targeting cancer cells, inhibiting cell growth or killing them. However, targeted therapies have the drawback that treatment responses vary significantly depending on a patient's genetic characteristics. Indeed, anti-EGFR drugs such as cetuximab (Erbitux®) are known to be effective first-line treatments for cancer, but only a small percentage of patients respond to them. Furthermore, anti-EGFR treatments are costly and difficult to predict. Therefore, while anti-EGFR drugs are administered to many patients in clinical trials, they only actually work in a small minority (20%).

[0003] To address these issues, PROTACs were developed. Because they do not require access to the active site of the POI, they are effective in treating "undruggable" proteins. However, PROTACs have limited efficacy as anticancer agents due to their small molecular structure and hydrophobicity, preventing them from achieving sufficient efficacy in clinical trials. Nanomaterials, including micelles, liposomes, and nanoparticles, have been developed to address the shortcomings of PROTACs. However, side effects caused by the nanomaterials used as carriers have been identified.

[0004] Therefore, there is an urgent need to develop a new platform-type anticancer drug that can achieve excellent anticancer effects while solving the problem of PROTAC.

[0005] Patent Document 1. Republic of Korea Patent Publication No. 10-1930399

[0006] The present invention has been devised to solve the above problems, and the present invention aims to provide a cancer targeting complex that binds to albumin in a living body and exists in a stabilized and inactive state, and a use thereof.

[0007] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer that can specifically penetrate cancer cells.

[0008] Another object of the present invention is to provide a food composition for preventing or improving cancer as described above.

[0009] To achieve the above object, the present invention provides a cancer targeting complex comprising: (i) a maleimide functional group; (ii) an esterase-cleavable linker connected to the functional group; and (iii) a PROTAC connected to the linker.

[0010] The linker is at least one non-peptide linker selected from the group consisting of a peptide linker comprising one or more amino acid sequences selected from the group consisting of G, GG and GGG, PABC (p-aminocarbamate), MBA (N,N'-mythylenebisacrylamide), alkylene linker, arylene linker, polyalkylene oxide linker (e.g., PEG), NHS ester linker, Triazene linker, hydrazone linker, disulfide linker, glucuronide-MABC linker, YSZ linker and dialkoxydiphenylsilane linker, or a linker in the form of a mixture of the peptide linker and the non-peptide linker, wherein Y is an azide (N3) or an alkylazide having 1 to 6 carbon atoms (-R'-N=N=N), wherein Z is any one selected from tetrazine, trans-cyclooctene and cyclooctene, and wherein S is any one selected from oligo or poly(ethylene glycol) (PEG), dextran, and an alkyl having 1 to 10 carbon atoms.

[0011] 상기 프로탁(PROTAC)은 CDK9(Cyclin-dependent kinase 9) / CDK family, BRD4(Bromodomain-containing protein 4) / BET(Bromodomain and extra-terminal) family, SHP-2(Src homology region 2 domain-containing phosphatase-2), AR(Androgen receptor), ER(Estrogen receptor), RAR(Retinoic acid receptor), ERRα(Estrogen-related receptor alpha), BTK(Bruton's tyrosine kinase), ALK(Anaplastic lymphoma kinase), RIPK(Receptor-interacting serine / threonine-protein kinase), c-Met(MET proto-oncogene / receptor tyrosine kinase), FAK(Focal adhesion kinase), IRAK4(Interleukin-1 receptor-associated kinase 4), p38 MAPK(p38 mitogen-activated protein kinases), SGK(Serum and glucocorticoid-regulated kinase), TBK1(TANK-binding kinase 1), KRAS(Kirsten rat sarcoma virus protein), B-Raf(B-Raf proto-oncogene serine / threonine kinase), β-catenin, FKBP(FK506 binding protein), IDO(Indoleamine 2,3-dioxygenase), PD-1 / PD-L1(Programmed death protein 1 / programmed death-ligand 1), PARP1(Poly [ADP-ribose] polymerase 1),PRC2 (Polycomb repressive complex 2), EGFR (Epidermal growth factor receptor), Sirt2 (NAD-dependent deacetylase sirtuin 2), HER2 / ERBB2 (Human epidermal growth factor receptor 2), FRS2 (Fibroblast growth factor receptor substrate 2), BCL-XL (B-cell lymphoma-extra large), SMARCA (SWI / SNF related matrix associated actin dependent regulator of chromatin subfamily A), HDM2 (Human double minute 2 homolog), HDAC (Histone deacetylase) family, BCR-ABL (Breakpoint cluster region protein- Tyrosine-protein kinase ABL1), MCL1 (Modulator Of VRAC Current 1), FLT-3 (Fms Related Receptor Tyrosine Kinase 3), STAT3 (Transcription factor STAT3), Myc family and BAF. At least one selected from the group consisting of complex (Brg / Brahma-associated factors) It may target proteins.

[0012] The above linker may be YSZ (Y is an azide (N3) group or an alkylazide having 1 to 6 carbon atoms (-R'-N=N=N, where R' is an alkyl group having 1 to 6 carbon atoms), Z is trans-cyclooctene or cyclooctene, and S is poly(ethylene glycol)), or may be a linker in the form of a mixture of a peptide linker composed of 1 to 3 glycines (G) and a non-peptide linker of poly(ethylene glycol).

[0013] The above cancer-targeting anticancer agent may be represented by the following chemical formula 1 or 2.

[0014] [Chemical Formula 1]

[0015]

[0016] [Chemical Formula 2]

[0017]

[0018] The above cancer targeting complex may be formed in a stabilized and inactivated form by binding to albumin existing in the body.

[0019] The above cancer-targeting complex may penetrate into cancer cells and be cleaved by esterase present in the cancer cells to release PROTAC.

[0020] In order to achieve the above-mentioned further object, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising a cancer targeting complex as an active ingredient.

[0021] The above cancer targeting complex may be formed in a stabilized and inactivated form by binding to albumin existing in the body.

[0022] The above cancer may be at least one selected from brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, duodenal cancer, appendix cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anal cancer, renal cancer, ureter cancer, bladder cancer, prostate cancer, penile cancer, testicular cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer, and skin cancer.

[0023] In order to achieve the above-mentioned further object, the present invention provides a food composition for preventing or improving cancer, which comprises a cancer-targeting complex as an active ingredient.

[0024] The present invention also provides a method for preventing or treating cancer, comprising administering a cancer-targeting complex to a subject.

[0025] The present invention also provides the use of a cancer targeting complex for the manufacture of a drug for the prevention or treatment of cancer.

[0026] When the cancer targeting complex according to the present invention is administered into a living body, it immediately binds to albumin and exists in a stable and inactive state, so it can provide enhanced cancer treatment, prevention, and improvement effects specific to cancer tissue without showing toxicity to normal tissue.

[0027] In particular, the cancer targeting complex according to the present invention penetrates deeply into cancer cells located in the center of cancer tissue as well as cancer tissue located near blood vessels, and thus has a significantly higher anticancer effect than an anticancer agent of the same amount.

[0028] Figure 1 is a schematic diagram illustrating the structure of a cancer-targeting complex according to the present invention and its pharmacodynamic process. Figure 1a illustrates the synthesis process of an albumin-binding esterase-cleavable BRD4-degrading PROTAC (ECMal-PROTAC) according to the present invention. Figure 1b illustrates the process in which the ECMal-PROTAC according to the present invention specifically binds to and degrades plasma albumin through a thiol-maleate reaction in blood vessels. Figure 1c illustrates the process in which the ECMal-PROTAC binds to albumin and then selectively accumulates in cancer tissues through the EPR effect. Figure 1d illustrates the process in which the albumin-bound ECMal-PROTAC selectively and easily enters cancer cells and is cleaved within the cancer cells to release free ARV-771. Figure 1e illustrates the mechanism of action of PROTAC in cancer cells. Free ARV-771 simultaneously binds to both BRD4 and VHL E3 ligase, inducing polyubiquitination of BRD4. The BRD4 / ARV-771 / E3 ligase complex then dissociates, and the polyubiquitinated BRD4 is taken up by the proteasome and degraded into oligopeptides. The dissociated ARV-771 is recycled and participates in the degradation of other BRD4 molecules.

[0029] Figure 1f illustrates the synthesis process of a cancer targeting complex according to the present invention and its pharmacological mechanism within cancer cells.

[0030] Figure 2 illustrates the chemical structure of a cancer targeting complex (ECMal-PROTAC) according to the present invention.

[0031] Figure 3a is the HPLC spectrum of ARV-771, N3-PROTAC, and cancer-targeting complex (ECMal-PROTAC).

[0032] Figure 3b is an LC-MS spectrum of a cancer targeting complex (ECMal-PROTAC) prepared from Example 1 ([M] + H + = 1586.7 m / z).

[0033] Figures 3c and 3d are HPLC and LC-MS spectra of ECMal-PROTAC prepared from Example 2.

[0034] Figure 4 is an HPLC spectrum of a mixture of BSA and a cancer-targeting complex (ECMal-PROTAC).

[0035] Figure 5 is an LC-MS spectrum for a mixture of BSA (Alb) and cancer targeting complex (ECMal-PROTAC).

[0036] Figure 6 shows HPLC spectra for a mixture of BSA and ARV-771, a mixture of thiol-blocked BSA and a cancer-targeting complex (ECMal-PROTAC), and a cancer-targeting complex (ECMal-PROTAC) and BSA.

[0037] Figure 7 is a graph showing the quantification of the HPLC peak area reduction associated with the cancer targeting complex (ECMal-PROTAC) from Figures 4 and 6.

[0038] Figure 8 shows the results of DLS analysis of the cancer targeting complex (ECMal-PROTAC) according to Example 1 before and after binding to albumin (BSA, albumin).

[0039] Figure 9 shows the results of HPLC analysis over time after treatment of Albumin-ECMal-PROTAC with esterase (15 units).

[0040] Figure 10 is a photograph taken using a confocal microscope of 4T1 cancer cells treated with Cy5.5-ARV-771 or Cy5.5-Alb-ECMal-PROTAC, and Figure 11 is a graph showing the quantification of intracellular fluorescence intensity in 4T1 cancer cells treated with Cy5.5-ARV-771 or Cy5.5-Alb-ECMal-PROTAC.

[0041] Figure 12 shows the results of Western blot analysis after treating 4T1 cancer cells with ARV-771 or the cancer targeting complex (ECMal-PROTAC) of Example 1.

[0042] Figure 13 is a graph quantifying the relative expression levels of c-Myc (a) and Bcl-2 (b) in 4T1 cancer cells treated with ARV-771 or the cancer targeting complex (ECMal-PROTAC) of Example 1.

[0043] Figure 14 is a graph quantifying the BRD4 expression level according to the concentration of ARV-771 or the cancer targeting complex (ECMal-PROTAC) of Example 1.

[0044] Figure 15 is a graph analyzing the survival rate after treating 4T1 cancer cells or MDA-MB231 with the cancer targeting complex (ECMal-PROTAC) of Example 1 (a) and the cancer targeting complex (Mal-PROTAC) of Example 2 (b).

[0045] Figure 16 shows a pharmacokinetic profile analyzing the plasma concentration according to administration time in the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC).

[0046] Figure 17 is a non-invasive near-infrared fluorescence (NIRF) photograph of the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC) over time.

[0047] Figure 18 is a graph (**** p < 0.0001) that quantifies only the fluorescence signal of cancer tissue from the results of the comparative group (Cy5.5-ARV-771 intravenous administration) and the experimental group (Cy5.5-Alb-ECMal-PROTAC intravenous administration) of Figure 17.

[0048] Figure 19 shows the ex vivo fluorescence images (a) and quantified fluorescence intensity graphs (b) of major organs (liver, lung, spleen, kidney, heart) and cancer tissues collected from the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC).

[0049] Figure 20 shows the fluorescence images (top) and quantified fluorescence intensity graphs (bottom) of cancer tissues collected from the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC) (*** p < 0.001).

[0050] Figure 21 is an enlarged fluorescence image of cancer tissues extracted from the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC).

[0051] Figure 22 is an image of cancer tissues extracted from the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC), stained with DAPI and CD31 markers, and then photographed using a confocal laser scanning microscope.

[0052] Figure 23 is an image of cancer tissue from the control group (Saline, control) administered saline instead of a sample, stained with DAPI and CD31 markers, and then photographed using a confocal laser scanning microscope.

[0053] Figure 24 is a graph depicting the fluorescence signal of cross-sections of cancer tissues extracted from the control group (control, saline), the comparative group (intravenous administration of Cy5.5-ARV-771), and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC).

[0054] Figure 25 is a graph showing the tumor size measured from the control group, comparison group, and experimental group over time (if there is no significant difference, it is indicated as ns. **** p < 0.0001).

[0055] Figure 26 is an optical image of cancer tissues extracted from the control group, comparison group, and experimental group.

[0056] Figure 27 is a confocal laser scanning image taken after TUNEL staining of cancer tissues extracted from the control group, comparison group, and experimental group.

[0057] Figure 28 is a graph showing the analysis of body weight changes in the control group, comparison group, and experimental group.

[0058] Figure 29 shows the results of histological analysis of organ tissues (liver, lung, spleen, kidney, heart) and cancer tissues extracted from the control group, comparative group, and experimental group.

[0059] Figure 30 shows the results of TUNEL analysis on liver tissues extracted from the control, comparative, and experimental groups.

[0060] Figure 31 shows the results of analyzing the expression levels of BRD4, c-Myc, and Bcl-2 using Western blot in cancer tissues extracted from the control group, comparison group, and experimental group.

[0061] Figure 32 is a graph that quantifies the results of Figure 31 (** p < 0.01, **** p < 0.0001).

[0062] Figure 33 is a photograph taken using a confocal laser scanning microscope of cancer tissues extracted from the control group (Control, Saline), the comparative group (ARV-771, intravenous administration), and the experimental group (ECMal-PROTAC, intravenous administration), after staining with DAPI, anti-BRD4, and anti-c-Myc.

[0063] Figure 34 shows the results of staining cancer tissues extracted from the control group, comparison group, and experimental group with DAB.

[0064] Hereinafter, the present invention will be described in detail.

[0065]

[0066] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.

[0067] In this specification, when a part is said to "include" a component, this does not mean that it excludes other components, but rather that it may include other components, unless specifically stated otherwise.

[0068] One aspect of the present invention relates to a cancer targeting complex comprising (i) a maleimide functional group; (ii) an esterase-cleavable linker connected to the functional group; and (iii) a PROTAC connected to the linker.

[0069] The linker is at least one non-peptide linker selected from the group consisting of a peptide linker comprising one or more amino acid sequences selected from the group consisting of G, GG and GGG, PABC (p-aminocarbamate), MBA (N,N'-mythylenebisacrylamide), alkylene linker, arylene linker, polyalkylene oxide linker (e.g., PEG), NHS ester linker, Triazene linker, hydrazone linker, disulfide linker, glucuronide-MABC linker, YSZ linker and dialkoxydiphenylsilane linker, or a linker in the form of a mixture of the peptide linker and the non-peptide linker, wherein Y is an azide (N3) or an alkylazide having 1 to 6 carbon atoms (-R'-N=N=N), wherein Z is any one selected from tetrazine, trans-cyclooctene and cyclooctene, and wherein S can be any one selected from oligo or poly(ethylene glycol) (PEG), dextran and an alkyl having 1 to 10 carbon atoms.

[0070] The cancer-targeting complex according to the present invention binds to endogenous albumin present in blood vessels in vivo through a thiol-maleimide reaction upon injection. Due to these structural characteristics, the cancer-targeting complex according to the present invention not only improves upon the low bioavailability, low targeting to tumor tissue, and accumulation rate of conventional PROTACs, but also exhibits significantly superior cancer treatment, prevention, and improvement effects.

[0071] The cancer targeting complex according to the present invention exists as a complex bound to albumin, easily accumulates in cancer cells through endocytosis, releases PROTAC by esterase present in cancer cells, and restores BRD4 degradation activity, thereby having a cancer cell-specific killing effect.

[0072] Figure 1 schematically illustrates the structure and pharmacodynamic mechanism of a cancer-targeting complex (ECMal-PROTAC) according to the present invention. Referring to this, the cancer-targeting complex according to the present invention will be described. The cancer-targeting complex of the present invention is a complex formed by combining an albumin-binding maleimide functional group (ECMal) with a PROTAC. The maleimide functional group and PROTAC may be directly bound or linked via a linker.

[0073] The above usable linker is not particularly limited to a linker specifically cleavable by esterase, but preferably includes a peptide linker comprising one or more amino acid sequences selected from the group consisting of G, GG and GGG, PABC (p-aminocarbamate), MBA (N,N'-mythylenebisacrylamide), alkylene linker, arylene linker, polyalkylene oxide linker (e.g., PEG), NHS ester linker, Triazene linker, hydrazone linker, disulfide linker, glucuronide-MABC linker, YSZ linker and dialkoxydiphenylsilane linker, or a linker in the form of a mixture of the peptide linker and the non-peptide linker, wherein Y is azide (N3), alkylazide having 1 to 6 carbon atoms (-R'-N=N=N), and Z is Any one selected from tetrazine, trans-cyclooctene and cyclooctene, wherein S may be any one selected from oligo or poly(ethylene glycol) (PEG), dextran and alkyl having 1 to 10 carbon atoms.

[0074] In the present invention, a peptide linker is a linker composed only of peptide residues, and is not particularly limited thereto as long as it can be cleaved by an esterase enzyme that exists in excess specifically in cancer cells, and preferably, it may be at least one selected from among G, GG, and GGG.

[0075] In the present invention, a non-peptide linker is a linker composed of a compound other than a peptide, and is not particularly limited thereto as long as it can be cleaved by an esterase enzyme specifically present in excess in cancer cells, but preferably may be at least one selected from the group consisting of PABC (p-aminocarbamate), MBA (N,N'-mythylenebisacrylamide), alkylene linker, arylene linker, polyalkylene oxide linker (e.g., PEG), NHS ester linker, Merrifield linker, Wang linker, Sasrin linker, Tritiyl linker, RINK-amide linker, Kenner linker, Silyl linker, Triazene linker, hydrazone linker, disulfide linker, glucuronide-MABC linker, YSZ linker, and dialkoxydiphenylsilane linker. The above Y is an azide (N3), an alkyl azide having 1 to 6 carbon atoms (-R'-N=N=N), the above Z is any one selected from tetrazine, trans-cyclooctene and cyclooctene, the above S may be any one selected from oligo or poly(ethylene glycol) (PEG), dextran and an alkyl having 1 to 10 carbon atoms, and preferably may be a polyalkylene oxide linker (e.g., PEG) or a YSZ linker.

[0076] In the present invention, the alkylene linker may be an alkylene linker having 2 to 20 carbon atoms, preferably an alkylene linker having 2 to 8 carbon atoms. The arylene linker may be a linker composed of an arylene group having 6 to 30 carbon atoms.

[0077] The above alkyl azide is an alkyl azide having 1 to 6 carbon atoms, and may be represented by -R'=N=N=N, and the R' may be an alkyl group having 1 to 6 carbon atoms.

[0078] The above cyclooctene may be any one selected from the group consisting of dibenzylcyclooctene (DBCO), difluorocyclooctene (DIFO), bicyclononine (BCN), dibenzoazacyclooctene (DIBAC), dibenzocyclooctynol (DIBO), and azadibenzocyclooctene (ADIBO).

[0079] In the present invention, the linker in which the peptide linker and the non-peptide linker are mixed means a linker formed by combining a peptide linker and a non-peptide linker, and the bonding order is not particularly limited, but preferably, it may be combined in the order of peptide linker-non-peptide linker. A preferred example of the linker in which the peptide linker and the non-peptide linker are mixed may be G-(PEG)m(m=1~5), GG-(PEG)m(m=1~5), or GGG-(PEG)m(m=1~5).

[0080] In one embodiment of the present invention, the linker (ii) may be YSZ (Y is an azide (N3) group or an alkylazide having 1 to 6 carbon atoms (-R'-N=N=N, where R' is an alkyl group having 1 to 6 carbon atoms), Z is trans-cyclooctene or cyclooctene, and S is poly(ethylene glycol)), or may be a linker in the form of a mixture of a peptide linker composed of 1 to 3 glycines (G) and a non-peptide linker of poly(ethylene glycol).

[0081] The cancer-targeting complex of the present invention releases PROTAC by cleaving the bond between PROTAC and the linker by esterase present within cancer cells. At this time, if even a small amount of the linker compound remains at one end of the PROTAC, or if the PROTAC structure is lost or damaged, the problem of significantly reduced activity occurs. Considering this, experiments were conducted on various linkers in the present invention, and as a result, it was confirmed that a linker cleavable by esterase is preferable, thereby completing the cancer-targeting complex of the present invention.

[0082] In the present invention, the linker has the advantage of being able to maintain the efficacy of PROTAC as it is completely cleaved by esterase present in cancer cells without damage or residue of PROTAC.

[0083] The term "proteolysis-targeting chimera (PROTAC)" used in the present invention is a platform technology composed of an E3 ligase binding module and a linker target protein binding module, which can induce degradation in vivo through ubiquitination of a disease-causing target protein, and can inhibit most disease-causing proteins that are difficult to inhibit with active site-directed drugs derived from existing drug development methods by degrading them.

[0084] 상기 프로탁(PROTAC)은 CDK9(Cyclin-dependent kinase 9) / CDK family, BRD4(Bromodomain-containing protein 4) / BET(Bromodomain and extra-terminal) family, SHP-2(Src homology region 2 domain-containing phosphatase-2), AR(Androgen receptor), ER(Estrogen receptor), RAR(Retinoic acid receptor), ERRα(Estrogen-related receptor alpha), BTK(Bruton's tyrosine kinase), ALK(Anaplastic lymphoma kinase), RIPK(Receptor-interacting serine / threonine-protein kinase), c-Met(MET proto-oncogene / receptor tyrosine kinase), FAK(Focal adhesion kinase), IRAK4(Interleukin-1 receptor-associated kinase 4), p38 MAPK(p38 mitogen-activated protein kinases), SGK(Serum and glucocorticoid-regulated kinase), TBK1(TANK-binding kinase 1), KRAS(Kirsten rat sarcoma virus protein), B-Raf(B-Raf proto-oncogene serine / threonine kinase), β-catenin, FKBP(FK506 binding protein), IDO(Indoleamine 2,3-dioxygenase), PD-1 / PD-L1(Programmed death protein 1 / programmed death-ligand 1), PARP1(Poly [ADP-ribose] polymerase 1),PRC2 (Polycomb repressive complex 2), EGFR (Epidermal growth factor receptor), Sirt2 (NAD-dependent deacetylase sirtuin 2), HER2 / ERBB2 (Human epidermal growth factor receptor 2), FRS2 (Fibroblast growth factor receptor substrate 2), BCL-XL (B-cell lymphoma-extra large), SMARCA (SWI / SNF related matrix associated actin dependent regulator of chromatin subfamily A), HDM2 (Human double minute 2 homolog), HDAC (Histone deacetylase) family, BCR-ABL (Breakpoint cluster region protein- Tyrosine-protein kinase ABL1), MCL1 (Modulator Of VRAC Current 1), FLT-3 (Fms Related Receptor Tyrosine Kinase 3), STAT3 (Transcription factor STAT3), Myc family and BAF. One or more factors selected from the group consisting of complex (Brg / Brahma-associated factors) It may target proteins.

[0085] The E3 ligase by which the above protac operates may exhibit a protein degradation effect through an E3 ligase selected from the group consisting of CRBN (Cereblon), VHL (Von Hippel-Lindau tumor suppressor), cIAP (Cellular inhibitor of apoptosis protein), Keap1 (Kelch-like ECH-associated protein 1), HDM2 (Human double minute 2 homolog), βTRCP (Beta-transducin repeat containing E3 ubiquitin protein ligase), CHIP (Carboxyl terminus of HSC70-interacting protein), and UHRF1 (ubiquitin like with PHD and ring finger domains 1). Specifically, the protein degradation effect may be exhibited through an E3 ligase selected from the group consisting of CRBN (Cereblon) and VHL (Von Hippel-Lindau tumor suppressor).

[0086] In one embodiment of the present invention, the cancer targeting complex according to the present invention may be represented by the following chemical formula 1 or 2.

[0087] [Chemical Formula 1]

[0088] /

[0089] [Chemical Formula 2]

[0090]

[0091] The above cancer targeting complex binds to albumin present in the body and is formed into a stabilized and inactivated form, so even if it exists in large quantities in the body, it does not exhibit toxicity in normal cells other than cancer tissue.

[0092] The above cancer-targeting complex penetrates into cancer cells, is cleaved by esterase present in the cancer cells, and releases PROTAC, thereby having an excellent anticancer effect.

[0093] The molecular weight of the cancer-targeting complex may be between 15 kDa and 25 kDa. If the molecular weight exceeds this, aggregation occurs, preventing effective entry into cancer cells. If the molecular weight is less than this, the complex is easily eliminated through the kidneys, reducing the retention time in the body.

[0094] The cancer-targeting complex according to the present invention is characterized by being cleaved by esterase. Since esterase exists in excess in cancer cells even without external stimulation, it is a target substance suitable for the structural characteristics of the present invention. Most conventional prodrug anticancer agents target caspases. However, if caspase is targeted due to the structural characteristics of the present invention, the release of PROTAC may not occur easily unless the cancer cell is first stimulated by an anticancer agent, etc., to increase the caspase concentration.

[0095] In one embodiment of the present invention, the PROTAC may be ARV-771. ARV-771 is composed of a BRD4 (bromodomain 4) inhibitor (JQ1) and a ligand for VHL (Von Hippel-Lindau) E3 ligase, and is one of the BRD4-degrading RPOTACs that degrades the BET (bromodomain and extra-terminal domain) protein and bromodomain to treat cancer. BET proteins are known to be overexpressed in cancer cells. The cancer-targeting complex according to the present invention is bound to the PROTAC via a linker that is connected to a maleimide group that forms a bond with albumin. Due to this structural feature, when the cancer-targeting complex according to the present invention is administered in vivo, it can form a bond with albumin present in the body, thereby achieving excellent tumor-specific accumulation and cell uptake.

[0096]

[0097] The synthesis process of the cancer targeting complex according to the present invention and the pharmacological mechanism against cancer cells are illustrated in Figure 1. In one embodiment of the present invention, ARV-771 (N3-PROTAC) having an azide group was prepared by combining PROTAC with 5-azidovaleric acid through Steglich esterification, and then the cancer targeting complex (ECMal-PROTAC) was synthesized through a copper-free alkyne-azide click reaction between N3-PROTAC and BCN-PEG2-Mal. In order to increase the purity of the cancer targeting complex prepared through the above-described process, a further purification step may be included, and column chromatography may preferably be used.

[0098]

[0099] Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a cancer-targeting complex as an active ingredient.

[0100] The above cancer targeting complex binds to albumin present in the body, forms a stabilized and inactivated form, and specifically accumulates in cancer cells, is specifically decomposed by esterase present in cancer cells, and releases PROTAC, thereby inducing cell death in cancer cells.

[0101] The term "cancer" used in the present invention refers to a general term for a disease caused by cells that have aggressive characteristics in which cells divide and grow while ignoring normal growth limits, invasive characteristics in which cells infiltrate surrounding tissues, and metastatic characteristics in which cells spread to other parts of the body.

[0102] In the present invention, the cancer is not particularly limited in type, and may be brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, duodenal cancer, appendix cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anal cancer, renal cancer, ureter cancer, bladder cancer, prostate cancer, penile cancer, testicular cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer, or skin cancer. In one embodiment of the present invention, the anticancer effect of combined administration of an IU1 series compound and Protac was confirmed in uterine cancer and prostate cancer cell lines, but is not limited thereto.

[0103] The term “prevention” used in the present invention means any act of suppressing or delaying the onset of cancer by administering a pharmaceutical composition according to the present invention.

[0104] The term "treatment" used in the present invention means any act in which symptoms of cancer are improved or beneficially changed by administration of the pharmaceutical composition according to the present invention.

[0105] The inventors of the present invention confirmed through specific examples that the cancer targeting complex according to the present invention can enhance the retention time of protac in the body, the cancer cell infiltration rate, and the anticancer effect.

[0106] In one embodiment of the present invention, it was confirmed that the cancer targeting complex significantly enhances the anticancer effect by reducing cancer proliferation by 5 to 6 times compared to when PROTAC is treated alone, and causing no damage to normal cells and causing damage through cell death only to cancer cells.

[0107] The present inventors have confirmed through various experimental examples below that when the cancer targeting complex of the present invention is administered, cancer-specific selectivity, cancer cell uptake rate, wide distribution to cancer cells, degradation effect of Protac on target proteins, and anticancer effect can be significantly enhanced, and thus, it can be widely utilized in the field of cancer treatment.

[0108] The above “cancer targeting complex” may be within the above-mentioned range.

[0109] The term "administration" in the present invention refers to introducing the pharmaceutical composition of the present invention into a subject by any suitable method, and the administration route may be administered through various oral or parenteral routes as long as it can reach the target tissue. Examples of parenteral administration routes include subcutaneous, intraperitoneal, intrapulmonary, intranasal, intramuscular, intravenous, or intraarterial, and intravenous administration is preferred.

[0110] The pharmaceutical composition of the present invention may further comprise a suitable carrier, excipient or diluent commonly used in the manufacture of pharmaceutical compositions. A composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral dosage forms. When formulated, the composition may be prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. Formulations for oral administration may include tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, and lyophilized preparations, and such preparations may be prepared by mixing one or more compounds with at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like.

[0111] In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives can be included. Preparations for parenteral administration can include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions can include propylene glycol, polyethylene glycol, and vegetable oils such as olive oil. Suppository bases can include witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin.

[0112] In addition, the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" in the present invention means an amount sufficient to inhibit or alleviate cancer at a reasonable benefit / risk ratio applicable to medical use, and the effective dosage level can be determined based on factors including the type and severity of the individual, age, body weight, diet, sex, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, treatment period, concurrently used drugs, and other factors well known in the medical field.

[0113] The pharmaceutical composition of the present invention may be administered once a day, divided into several doses, once every other day, or once a week. Specifically, the pharmaceutical composition may be administered at a dose of 0.001 to 1000 mg / kg / day, and more specifically, at a dose of 0.1 to 100 mg / kg / day.

[0114] Furthermore, the composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent. When administered in combination with another therapeutic agent, the composition of the present invention and the other therapeutic agent may be administered sequentially or simultaneously. The other therapeutic agent may be a drug, such as a compound or protein, that promotes cancer regression or further prevents cancer proliferation or growth. It also includes all other anticancer therapies other than drug therapy, such as radiation therapy.

[0115]

[0116] Another aspect of the present invention relates to a food composition for preventing or improving cancer, comprising the cancer-targeting complex as an active ingredient.

[0117] The above “cancer targeting complex”, “protac”, “cancer”, “prevention”, etc. may be within the aforementioned scope.

[0118] The food composition of the present invention has an excellent effect in preventing or improving cancer.

[0119] The term "improvement" as described above may refer to any action that at least reduces a parameter related to the condition being treated, such as the severity of symptoms. In this case, the food composition may be used before or after the onset of the disease, or concurrently with or separately from a therapeutic agent, to prevent or improve cancer.

[0120] In the above food composition, the active ingredient can be added directly to the food or used in combination with other foods or food ingredients, and can be used appropriately according to conventional methods. The amount of the active ingredient mixed can be appropriately determined depending on its intended use (prevention or improvement). Generally, when manufacturing a food or beverage, the food composition can be added in an amount of about 15% by weight or less, more specifically about 10% by weight or less, based on the raw material. However, in the case of long-term consumption for the purpose of health and hygiene or health control, the amount may be below the above range.

[0121] The above food composition may be formulated into one selected from the group consisting of tablets, pills, powders, granules, powders, capsules, and liquid formulations, further comprising one or more of a carrier, a diluent, an excipient, and an additive. Foods to which the compound according to one aspect may be added include various foods, powders, granules, tablets, capsules, syrups, beverages, gum, tea, vitamin complexes, and health functional foods.

[0122] Specific examples of the carrier, excipient, diluent and additive may include at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

[0123] In addition to containing the above-described effective ingredient, the above-described food composition may contain other ingredients as essential ingredients without particular limitation. For example, it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. Examples of the above-described natural carbohydrates include conventional sugars such as monosaccharides, such as glucose, fructose, etc.; disaccharides, such as maltose, sucrose, etc.; and polysaccharides, such as dextrin, cyclodextrin, etc.; and sugar alcohols such as xylitol, sorbitol, erythritol, etc. In addition to the above-described flavoring agents, natural flavoring agents (thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the above-described natural carbohydrates can be appropriately determined by a person skilled in the art.

[0124] In addition to the above, the food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. These components may be used independently or in combination, and the ratio of these additives may also be appropriately selected by those skilled in the art.

[0125] The above food composition can be used as a health functional food for preventing or improving cancer.

[0126] The above food composition may be provided mixed with a health functional food for preventing or improving cancer known in the past or a health functional food for preventing or improving cancer that is newly developed.

[0127] If the above health functional food further includes a health functional food for preventing or improving cancer, it is important to mix the amount that can achieve the maximum effect with the minimum amount without causing side effects, and this can be easily determined by a person skilled in the art.

[0128]

[0129] Another aspect of the present invention provides a method for preventing or treating cancer, comprising administering to a subject the cancer-targeting complex.

[0130] The above “cancer targeting complex”, “protac”, “administration”, “cancer”, “prevention”, “treatment”, etc. may be within the scope described above.

[0131] The term "subject" in the present invention refers to any animal, including humans, that is susceptible to or has developed cancer. By administering the composition of the present invention to a subject, cancer can be alleviated or treated.

[0132] The above method may be administered in conjunction with a known composition or other pharmaceutical composition having a cancer prevention or treatment effect, or may be administered simultaneously, separately, or sequentially, or may be administered singly or in multiple doses. Taking all of the above factors into account, it is important to administer the amount that achieves maximum effect with the minimum amount possible without causing side effects, and this can be readily determined by those skilled in the art.

[0133]

[0134] Another aspect of the present invention provides the use of a cancer targeting complex for the manufacture of a medicament for the prevention or treatment of cancer.

[0135] The above “cancer”, “prevention”, “treatment”, “cancer targeting complex”, “protac”, etc. may be within the scope described above.

[0136]

[0137] Hereinafter, the present invention will be described in more detail through examples and the like. However, the scope and content of the present invention should not be construed as being limited or reduced by the examples and the like. Furthermore, based on the disclosure of the present invention, including the following examples, it is clear that those skilled in the art can easily implement the present invention, even though specific experimental results are not presented. It is also natural that such variations and modifications fall within the scope of the appended claims.

[0138] In addition, the experimental results presented below only describe representative experimental results of the above examples and comparative examples, and the effects of each of the various embodiments of the present invention that are not explicitly presented below will be specifically described in the relevant section.

[0139]

[0140] Experimental materials

[0141] In this experiment, ARV-771 (99.02%) was obtained from Chemscene (Monmouth Junction, NJ, USA). DMF (N,N-dimethylformamide; 99.8%), EDC-HCl (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride), DMAP (4-dimethylaminopyridine; 99%), porcine liver esterase, and TEA (triethylamine; 99.5%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-Azidovaleric acid (98%), 4-maleimidobutyric acid (98%), and 2-mercaptoethanol (98%) were commercially obtained from Tokyo Chemical Industry (TCI; Toshima, Tokyo, Japan). BCN-PEG2-Mal (Bicyclononyne-polyethylene glycol-maleimide; 95%) was purchased from Axispharm (San Diego, CA, USA), and acetonitrile (ACN) was purchased from Honeywell (Charlotte, NC, USA). DMSO (Dimethyl sulfoxide; 99%), BSA (bovine serum albumin; 98%), and TWEEN 20 were purchased from Biosesang (Ansan, Gyeonggi, Republic of Korea). Cy5.5-NHS (Cyanine 5.5-N-hydroxysuccinimide ester) and Cy5.5-COOH (cyanine 5.5.5-carboxylic acid) was purchased from Lumiprobe (Hunt Valley, MD, USA), and anti-BRD4, anti-c-Myc, anti-Bcl-2, and anti-β-actin were purchased from Abcam (Discovery Drive, Cambridge, United Kingdom). CCK-8 (Cell counting kit-8) was purchased from Vitascientific (Beltsville, MD, USA), and RPMI (Roswell Park Memorial Institute) 1640 medium, FBS (fetal bovine serum), penicillin, and streptomycin were purchased from WELGENE Inc (Daegu, Republic of Korea). 4T1 (mouse breast cancer cells) cell line was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). All reagents were used as received.

[0142]

[0143] experimental equipment

[0144] Reverse-phase high-performance liquid chromatography (RP-HPLC; 1200 series, Agilent Technologies, Palo Alto, CA, USA) equipped with a C18 column (Eclipse XDB-C18, 4.6 × 150 mm, particle size = 5 μm, Agilent Technologies) was used. The molar masses and their m / z (mass-to-charge ratios) of the products in all synthetic procedures were determined by liquid chromatography-mass spectrometry (LC-MS; Q-TOF 5600, AB SCIEX, Framingham, MA, USA). The hydrodynamic size of albumin was measured by dynamic light scattering (DLS; Zetasizer Nano ZS, Malvern Instruments, Malvern, UK). Chemical conjugation of FITC or Cy 5.5 dyes to ARV-771 or BSA was verified by fluorescence spectrophotometry (FL; Hitachi F-7000, Hitachi High-Tech, Hitachinaka, Ibaraki, Japan). Observations were performed using a confocal laser scanning microscope (CLSM; Leica TCS SP8, Leica Microsystems GmbH, Wetzlar, Germany) and a microplate reader (VERSAmaxTM, Molecular Devices Corp., Sunnyvale, CA, USA). The in vivo and ex vivo biodistribution of the cancer-targeting complex (ECMal-PROTAC) was investigated using an IVIS Lumina Series III system (PerkinElmer, Waltham, MA, USA) with Living Image software (PerkinElmer).

[0145]

[0146] Statistical analysis

[0147] All statistical data in this study are expressed as the mean ± standard deviation (SD) from at least three independent experiments. Statistical analysis between two groups was performed using the Student's t-test. For comparisons of more than two groups, a one-way analysis of variance (ANOVA) test was used, and statistical significance for multiple comparisons was tested using the Tukey-Kramer test. The p-value of each statistical data is indicated numerically by an asterisk (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

[0148]

[0149] Manufacturing Example 1. Manufacturing of Cy5.5 conjugated to BSA and ARV-771

[0150] To investigate the in vitro intracellular uptake, in vivo pharmacokinetic properties, and biodistribution of Alb-ECMal-PROTAC and ARV-771, Cy5.5-conjugated ARV-771 and BSA were synthesized. Specifically, ARV-771 (5 mg, 5.07 μmol), Cy5.5-COOH (5.8 mg, 7.60 μmol), and DMAP (3.1 mg, 25.34 μmol) were placed in a 4 mL vial and dissolved by adding 1 mL anhydrous DMF. EDC-HCl (3.9 mg, 25.34 μmol) was added to the vial. This activated the carboxylic acid group of Cy5.5-COOH. The crude product was obtained after a reaction at room temperature for 12 h. The above crude product was passed through a C18 column using ACN / H2O (40 / 60) as an eluent to recover pure Cy5.5-conjugated ARV-771 (Cy5.5-ARV-771).

[0151] To obtain Cy5.5-labeled BSA (Cy5.5-Alb), unlabeled BSA (66.5 mg, 1.00 μmol) and Cy5.5-NHS (0.1 mg, 0.10 μmol) were mixed and dissolved in 10 mL anhydrous DMF. The mixture was allowed to react at room temperature for 12 h to obtain the reactant. After the reaction was completed, the reactant was recovered, diluted with H2O, dialyzed using a dialysis membrane (MWCO = 10,000 Da), and lyophilized to prepare Cy5.5-Alb with a molar ratio of 1:10 of Cy5.5 to BSA.

[0152] The fluorescence intensities of Cy5.5-ARV-771 and Cy5.5-Alb were quantified by FL, and Cy5.5-ARV-771 was further blended with native ARV-771 so that the molar ratio of Cy5.5 and ARV-771 was 1:10.

[0153]

[0154] Example 1. Synthesis of ECMal-PROTAC

[0155] [Reaction Formula 1]

[0156]

[0157] ARV-771 (20.0 mg, 20.27 μmol) was placed in a 3 ml 1-neck round bottom flask equipped with a magnetic stirrer bar, and 0.5 ml anhydrous DMF was added to dissolve it.

[0158] 5-azidovaleric acid (7.25 mg, 50.68 μmol), DMAP (12.38 mg, 101.35 μmol), and EDC-HCl (15.73 mg, 101.35 μmol) were successfully added to the flask, and the mixture was reacted at room temperature with gentle mixing for 12 h. The resulting crude was concentrated under reduced pressure, and N3-PROTAC was separated by C18 column chromatography (Sep-Pak® C18 cartridges 5 g; Waters Corporation, Milford, MA, USA) using an eluent of ACN / H2O (70 / 30, v / v). The recovered N3-PROTAC was lyophilized to remove residual solvent.

[0159] For the synthesis of ECMal-PROTAC, N3-PROTAC (20.0 mg, 17.99 μmol) was placed in a 3 ml single-neck round-bottom flask and dissolved in 0.5 ml DMSO. BCN-PEG2-Mal (12.8 mg, 26.98 μmol) was added to the solution and reacted at room temperature for 2 hours. The crude product was passed through a C18 preparative column of RP-HPLC. A gradient elution of ACN / H2O from 20 / 80 to 80 / 20 (v / v) was used, and the product was lyophilized to isolate pure ECMal-PROTAC powder. The products obtained at each step were confirmed through RP-HPLC and LC-MS analyses. RP-HPLC and LC-MS analyses confirmed the successful synthesis of high-purity ECMal-PROTAC (N3-PROTAC: 88.7% yield, 98.9% purity, ECmal-PROTAC: 62.9% yield and 98.2% purity) (Figs. 3a and 3b). As shown in Fig. 3a, each spectrum shows a full shift of the corresponding peak for each reaction, indicating that the chemical conjugation was performed completely successfully without any significant side effects. As shown in Fig. 3b, the molecular weight measured through the LC-MS spectrum was similar to the theoretical value (m / z = 1586.7, [M] + 1H+).

[0160]

[0161] Example 2. Mal-PROTAC synthesis

[0162] [Reaction Formula 2]

[0163]

[0164] ARV-771 (20.0 mg, 20.27 μmol) was placed in a 3 ml single-neck round-bottom flask equipped with a magnetic stirrer bar and dissolved by adding 0.5 ml anhydrous DMF. Fmoc-Gly-OH (12.1 mg, 40.54 μmol), DMAP (7.43 mg, 60.81 μmol), and EDC-HCl (9.44 mg, 60.81 μmol) were successfully added to the flask, and the mixture was reacted at room temperature with gentle mixing for 12 h. The resulting crude was concentrated under pressure, and Fmoc-Gly-PROTAC was separated by C18 column chromatography (Sep-Pak® C18 cartridges 5 g; Waters Corporation, Milford, MA, USA) using ACN / H2O (70 / 30, v / v) as eluent to obtain Fmoc-Gly-PROTAC. The recovered Fmoc-Gly-PROTAC was lyophilized to remove residual solvent.

[0165] For the removal of the Fmoc protecting group, Fmoc-Gly-PROTAC (20.0 mg, 15.80 μmol) was placed in a 3 ml, single-necked, round-bottomed flask equipped with a magnetic stirrer bar, and 0.5 ml of a 20% (v / v) piperidine / DMF mixture solution was added to dissolve and reacted at room temperature for 15 min. The resulting crude was concentrated under reduced pressure, and Gly-PROTAC was separated by C18 column chromatography (Sep-Pak® C18 cartridges 5 g; Waters Corporation, Milford, MA, USA) using an eluent of ACN / H2O (50 / 50, v / v). The recovered Fmoc-Gly-PROTAC was lyophilized to remove residual solvent.

[0166] To synthesize Mal-PROTAC, Gly-PROTAC (15.0 mg, 14.37 μmol) was placed in a 3-ml single-neck round-bottom flask equipped with a magnetic stirrer bar, and 0.5 ml anhydrous DMF was added to dissolve it. Maleimide-PEG2-NHS Ester (12.23 mg, 28.74 μmol) and DIPEA (7.51 μl, 43.12 μmol) were successfully added to the solution, and the mixture was reacted at room temperature for 12 h. The resulting crude was concentrated under reduced pressure and passed through a C18 preparative column of RP-HPLC. A gradient elution of ACN / H2O from 20 / 80 to 80 / 20 (v / v) was used, and the pure Mal-PROTAC powder was lyophilized to isolate it.

[0167]

[0168] Experimental Example 1. In vitro binding rate of ECMal-PROTAC prepared from Example 1 to albumin

[0169] The binding rate of ECMal-PROTAC and albumin of Example 1 was confirmed through RP-HPLC. Specifically, a BSA solution (200 μM) diluted with PBS was co-incubated with the ECMal-PROTAC aqueous solution (140 μM) of Example 1 at a 1:1 volume ratio. The culture was harvested at incubation times of 0, 5, 30, and 60 minutes, quenched with mercaptoethanol, and HPLC spectra for each sample were acquired through a concentration gradient of the eluent (ACN / H2O, 20 / 80 to 80 / 20 (v / v), 30 minutes).

[0170] To verify the albumin binding ability of ECMal-PROTAC of Example 1, a mixture of BSA and cancer-targeting complex (ECMal-PROTAC) was analyzed by LC-MS spectrum, and compared with the LC-MS spectrum of free BSA.

[0171] In a mixture of BSA and the cancer targeting complex (ECMal-PROTAC) of Example 1, BSA-bound ECMal-PROTAC (Alb-ECMal-PROTAC) is formed through a thiol-maleimide reaction, and since almost all cancer targeting complexes bind to albumin to form Alb-ECMal-PROTAC, in some experimental examples, a mixture of BSA and the cancer targeting complex (ECMal-PROTAC) and Alb-ECMal-PROTAC can be used together.

[0172]

[0173] Figure 4 is an HPLC spectrum of a mixture of BSA and a cancer-targeting complex (ECMal-PROTAC), which shows that BSA and the cancer-targeting complex (ECMal-PROTAC) rapidly bind through a thiol-maleimide click chemistry reaction. The cancer-targeting complex (ECMal-PROTAC) of Example 1 was analyzed using bovine serum albumin (BSA), which has a structure similar to human serum albumin (HSA), to confirm its albumin binding ability. When the cancer-targeting complex (ECMal-PROTAC) of Example 1 was mixed with BSA and analyzed over time by RP-HPLC, it was confirmed that the peak of the cancer-targeting complex (ECMal-PROTAC) rapidly decreased and the peak of BSA gradually broadened.

[0174]

[0175] Figure 5 shows the LC-MS spectrum for a mixture of BSA and the cancer-targeting complex (ECMal-PROTAC). BSA and the cancer-targeting complex (ECMal-PROTAC) alone were also analyzed by LC-MS and are shown in Figure 5.

[0176] According to FIG. 5, the change in molecular weight of the cancer-targeting complex (ECMal-PROTAC) and Alb-ECMal-PROTAC according to Example 1 was confirmed to be 1,587 Da. It can be confirmed that this is consistent with the change in molecular weight of the cancer-targeting complex (ECMal-PROTAC) according to Example 1. In other words, it can be seen that the cancer-targeting complex (ECMal-PROTAC) according to Example 1 safely binds to albumin without chemical or physical changes.

[0177]

[0178] Experimental Example 2. Selective binding properties of ECMal-PROTAC prepared from Example 1 and albumin in vitro

[0179] To confirm whether the binding of ECMal-PROTAC of Example 1 to albumin was specific, thiol-blocked BSA was used. Specifically, thiol-blocked BSA was prepared by mixing BSA with 4-maleimidobutyric acid, a cyc34 blocker. The thiol-blocked BSA was diluted with PBS to prepare a solution (200 μM), which was co-incubated by mixing it with the aqueous ECMal-PROTAC solution (140 μM) of Example 1 at a 1:1 volume ratio. The culture was harvested at incubation times of 0, 5, 30, and 60 min, quenched with mercaptoethanol, and HPLC spectra for each sample were acquired through a gradient eluent (ACN / H2O, 20 / 80 to 80 / 20 (v / v), 30 min).

[0180] At this time, as a comparative example, the HPLC spectra were analyzed for co-culture in which ARV-771 (140 μM) and BSA solution (200 μM) were mixed in a volume ratio of 1:1, and for the ECMal-PROTAC solution of Example 1 and the BSA solution alone without any treatment.

[0181] From the HPLC results for the mixture of BSA and cancer-targeting complex (ECMal-PROTAC) in Experimental Example 1 and the mixture of thiol-blocked BSA and cancer-targeting complex (ECMal-PROTAC) in Experimental Example 2, the decrease in HPLC peak area associated with the cancer-targeting complex (ECMal-PROTAC) was quantified. This was calculated through changes in peak integration and is shown in Figure 7.

[0182]

[0183] Figure 6 shows HPLC spectra for a mixture of BSA and ARV-771, a mixture of thiol-blocked BSA and a cancer-targeting complex (ECMal-PROTAC), and the cancer-targeting complex (ECMal-PROTAC) and BSA. Figure 7 is a graph quantifying the decrease in HPLC peak area associated with the cancer-targeting complex (ECMal-PROTAC) from Figures 4 and 6.

[0184] According to Figure 6, it can be confirmed that ARV-771 does not form an interaction with BSA even when mixed for more than 60 minutes. In addition, it was confirmed that a mixture of thiol-blocked BSA and a cancer-targeting complex (ECMal-PROTAC) also does not form an interaction. In other words, it can be seen that the cancer-targeting complex (ECMal-PROTAC) of Example 1 and BSA exhibit a site-specific reaction.

[0185] According to Figure 7, it was confirmed that the thiol-maleimide reaction of BSA and the cancer-targeting complex (ECMal-PROTAC) was completed by more than 75% within 3 minutes, and 100% within 10 minutes.

[0186]

[0187] Experimental Example 3. Particle Size Analysis of Alb-ECMal-PROTAC

[0188] A BSA solution (200 μM) diluted with PBS was co-incubated with the ECMal-PROTAC aqueous solution (140 μM) of Example 1 at a 1:1 volume ratio. The culture was harvested after 30 minutes to obtain Alb-ECMal-PROTAC. The particle sizes of Alb-ECMal-PROTAC and BSA were measured by DLS.

[0189] Figure 8 shows the results of DLS analysis of the cancer-targeting complex (ECMal-PROTAC) according to Example 1 before and after binding to albumin (BSA), which shows that no significant change in particle size was observed when ECMal-PROTAC was bound to albumin. The average particle sizes of native BSA and Alb-ECMal-PROTAC were 5.43 ± 1.42 and 6.99 ± 1.38 nm, respectively, indicating that binding of albumin to ECMal-PROTAC did not induce degradation or aggregation.

[0190]

[0191] Experimental Example 4. Confirmation that the cancer-targeting complex (ECMal-PROTAC) of Example 1 is degraded under esterase conditions after binding to albumin.

[0192] A BSA solution (200 μM) diluted with PBS was co-incubated with the ECMal-PROTAC aqueous solution (140 μM) of Example 1 at a 1:1 volume ratio. The culture was reacted for 30 minutes at pH 8.0 and then harvested to obtain Alb-ECMal-PROTAC. 15 units of esterase were added to 0.2 ml of the Alb-ECMal-PROTAC aqueous solution, and the mixture was harvested at reaction times of 0, 3, 6, and 9 hours and analyzed by RP-HPLC. Free ARV-771 was used as a control.

[0193] Since the cancer targeting complex (ECMal-PROTAC) of Example 1 is internalized into cancer cells in an albumin-bound form under physiological conditions, Alb-ECMal-PROTAC was used instead of the cancer targeting complex (ECMal-PROTAC) of Example 1.

[0194]

[0195] Figure 9 shows the results of HPLC analysis over time after treating Alb-ECMal-PROTAC with esterase (15 units). According to Figure 9, Alb-ECMal-PROTAC was confirmed to have gradual release of ARV-771 due to cleavage of ester bonds by esterase. It was confirmed that Alb-ECMal-PROTAC released 63.2% of ARV-771 within 48 hours. This experiment was conducted in vitro, and it is thought that the degradation rate in vivo will be accelerated by acidic pH. In addition, since BSA and HSA derived from mammalian plasma are structurally very similar, it is thought that it will also have excellent binding and decomposition effects in HSA.

[0196]

[0197] Experimental Example 5. In vitro, analysis of cell uptake of ECMal-PROTAC of Example 1

[0198] The cancer-targeting complex (ECMal-PROTAC) of Example 1 showed improved cellular uptake through significantly enhanced endocytosis. To confirm this, a Cy5.5-BSA solution (Cy5.5-Alb, Preparation Example 1, 200 μM) diluted with PBS was mixed with the ECMal-PROTAC aqueous solution (140 μM) of Example 1 at a 1:1 volume ratio and co-incubated. The culture was reacted for 30 minutes under pH 8.0 conditions and then harvested to obtain Cy5.5-Alb-ECMal-PROTAC. Cy5.5-ARV-771 of Preparation Example 1 was used as a control.

[0199] Prepare 4T1 mouse breast cancer cell line, 1 × 10 5 4T1 cells were seeded onto glass-bottom confocal dishes (35 mm in diameter) and cultured in RPMI medium for 24 h. After stabilization, the cells were treated with Cy5.5-ARV-771 (5 μM) or Cy5.5-Alb-ECMal-PROTAC (5 μM) and cultured at 37°C for 1, 3, 6, and 12 h. The cells were washed three times with PBS and treated with 4% formaldehyde aqueous solution for 15 min. The nuclei of the cells were then stained with DAPI (4,6-diamidino-2-phenylindole) for 10 min. The DAPI and Cy5.5 fluorescence signals in the 4T1 cells were measured and analyzed using CLSM. The cellular uptake of ARV-771 and Alb-ECMal-PROTAC over time was evaluated using the analysis results. The relative intracellular fluorescence intensity of FITC was calculated using Image-Pro software (Media Cybernetics, Rockville, MD, USA), and the change was expressed as a function of time.

[0200]

[0201] Figure 10 is a photograph taken using a confocal microscope of 4T1 cancer cells treated with Cy5.5-ARV-771 or Cy5.5-Alb-ECMal-PROTAC, and Figure 11 is a graph showing the quantification of intracellular fluorescence intensity in 4T1 cancer cells treated with Cy5.5-ARV-771 or Cy5.5-Alb-ECMal-PROTAC.

[0202] According to Figure 10, both Cy5.5-ARV-771 and Cy5.5-Alb-ECMal-PROTAC were gradually absorbed into 4T1 cells within 12 hours. The concentrations of Cy5.5-ARV-771 and Cy5.5-Alb-ECMal-PROTAC absorbed into the cells were also confirmed to be similar (relative fluorescence intensities of 0.61 ± 0.11 and 0.61 ± 0.06, respectively). However, the cellular uptake rate of Cy5.5-Alb-ECMal-PROTAC was confirmed to be slightly faster than that of Cy5.5-ARV-711. This indicates that the cancer-targeting complex (ECMal-PROTAC) of Example 1 binds to albumin in vivo and tends to be actively absorbed into cancer cells due to this structural feature.

[0203]

[0204] Experimental Example 6. Therapeutic effect of ECMal-PROTAC of Example 1 in vitro

[0205] BRD4 is a protein that regulates gene transcription and is known to be significantly involved in the transcription of cancer-related genes. Therefore, silencing BRD4 in cancer cells suppresses oncogene transcription, inducing apoptosis.

[0206] Accordingly, when cancer cells were treated with the cancer-targeting complex (ECMal-PROTAC) of Example 1, Western blot analysis was performed to evaluate the removal of BRD4 and other related proteins (e.g., c-Myc and Bcl-2) to confirm the cancer therapeutic effect. The cancer-targeting complex (ECMal-PROTAC) of Example 1 and ARV-771 were prepared as samples.

[0207] First, 1 × 10 54T1 cells were seeded into each well of a 6-well culture plate and cultured for 24 hours at 37°C in a 5% carbon dioxide atmosphere. Various concentrations of ARV-771 (0 to 10 μM) or the cancer-targeting complex (ECMal-PROTAC) of Example 1 (0 to 10 μM) were added to the cell culture medium and cultured at 37°C for 24 hours. After completion of the culture, the cells were washed three times with PBS and lysed with a lysis buffer containing 1% protease. Cell debris from the collected lysate was removed by centrifugation at 12,000 rpm for 25 minutes, and the supernatant was collected, and the protein amount was measured using a BCA kit. The supernatant was loaded onto a 10% sodium dodecyl sulfate-polyacrylamide gel, subjected to electrophoresis (SDS-PAGE), and then blotted onto a polyvinylidene difluoride (PVDF) membrane. After blotting, the PVDF membrane was treated with 5% BSA-containing tris-buffered saline (TBS-T) containing 0.1% Tween 20 (BSA-containing tris-buffered saline) for 2 h to inhibit indiscriminate binding of IgG (immunoglobulin G), and then immediately exposed to a rabbit anti-mouse primary antibody (1,000:1). After 24 h at 4°C, the PVDF membrane was washed three times with TBS-T and then incubated with an HRP-conjugated mouse anti-rabbit IgG antibody for an additional 1 h at room temperature. Immunoreactive bands on the PVDF membrane were analyzed using an enhanced chemiluminescence (ECL) system.

[0208]

[0209] Figure 12 shows the results of Western blot analysis after treating 4T1 cancer cells with ARV-771 or the cancer targeting complex (ECMal-PROTAC) of Example 1. Figure 13 is a graph quantifying the relative expression levels of c-Myc (a) and Bcl-2 (b) in 4T1 cancer cells treated with ARV-771 or the cancer targeting complex (ECMal-PROTAC) of Example 1. Figure 14 is a graph quantifying the BRD4 expression level according to the concentration of ARV-771 or the cancer targeting complex (ECMal-PROTAC) of Example 1.

[0210] According to Figures 12 to 14, the cancer-targeting complex (ECMal-PROTAC) of Example 1 was confirmed to bind to mouse serum albumin (MSA) in a cell culture medium, be efficiently internalized into 4T1 cells, and degrade overexpressed BRD4 protein in a concentration-dependent manner. Therefore, it can be seen that the cancer-targeting complex (ECMal-PROTAC) of Example 1 is successfully degraded by esterase present in cancer cells to release ARV-771.

[0211] According to Figure 13, the cancer-targeting complex (ECMal-PROTAC) of Example 1 was also confirmed to reduce the levels of other proteins such as C-Myc and Bcl-2. C-Myc and Bcl-2 play an important role in BRD4 mRNA transcription, indicating that they are effectively involved in BRD4 degradation.

[0212] According to Figure 14, the results of quantifying the band of BRD4 showed that the DC of the cancer targeting complex (ECMal-PROTAC) of Example 1 50 (half-maximal degradation concentration) was confirmed to be 1.81 μM. This is ARV-771(DC 50=3.38 μM). In summary of the above results, it was confirmed that the cancer-targeting complex (ECMal-PROTAC) of Example 1 was successfully absorbed into cancer cells through endocytosis, and the ECmal linker was cleaved by esterase present in the cancer cells to efficiently release PROTAC, thereby inducing cancer cell death.

[0213]

[0214] Experimental Example 7. In vitro, the cancer cell therapeutic effect of the cancer targeting complex (ECMal-PROTAC) of Example 1

[0215] The toxicity of ARV-771 and ECMal-PROTAC to cancer cells was analyzed using the CCK-8 (cell counting kit-8) assay. 4T1 cells were seeded at 3 × 10 per well in 96-well culture plates. 3 The cells were seeded and cultured for 24 hours at 37°C in a 5% carbon dioxide atmosphere. The cells were treated with different concentrations of ARV-771 (0.01 to 100 μM), the cancer-targeting complex (ECMal-PROTAC) of Example 1 (0.01 to 100 μM), and the cancer-targeting complex (Mal-PROTAC) of Example 2 (0.01 to 100 μM), respectively, and cultured for 48 hours. After exposing each well to 10% CCK-8-containing culture media for 30 minutes, the viability of 4T1 cells treated with ARV-771 or 4T1 cells treated with ECMal-PROTAC or Mal-PROTAC was analyzed using a microplate reader. Changes in cell viability according to the concentration of ARV-771 or ECMal-PROTAC or Mal-PROTAC were fitted using GraphPad Prism 8 software (GraphPad Software, San Diego, CA, USA) and IC 50(Half-maximal inhibitory concentration) values ​​were calculated.

[0216]

[0217] Figure 15 is a graph analyzing the survival rate after treating 4T1 cancer cells with the cancer targeting complex (ECMal-PROTAC) of Example 1 (a) and the cancer targeting complex (Mal-PROTAC) of Example 2 (b).

[0218] According to Figure 15, the cancer targeting complex (ECMal-PROTAC) of Example 1 has an IC of 7.780 μM against cancer cells. 50 It was confirmed that the cancer targeting complex according to the present invention has notable anti-proliferative properties against cancer cells rich in BRD4.

[0219] When the cancer targeting complex (ECMal-PROTAC) of Example 1 and the cancer targeting complex (Mal-PROTAC) of Example 2 are intracellularly introduced, they induce BRD4 deficiency and a decrease in the expression of c-Myc and Bcl-2, which are downstream effectors of BRD4, thereby promoting apoptosis of cancer cells. The cancer targeting complex (ECMal-PROTAC) of Example 1 and the cancer targeting complex (Mal-PROTAC) of Example 2 exist in vivo in an inactive state by binding to albumin in vivo, thereby causing native ARV-771 (IC 50 IC = 6.375 μM) compared to 50 Although this is considered to be a slight increase, it can still be considered a remarkable effect for anticancer treatment. Therefore, it can be seen that the cancer targeting complex (ECMal-PROTAC, Mal-PROTAC) according to the present invention can be easily utilized as an anticancer agent because it promotes BRD4 degradation and successfully recruits the VHL E3 pathway to induce excellent cancer cell death.

[0220]

[0221] Experimental Example 8. Analysis of the biodistribution and cancer targeting potential of the cancer-targeting complex (ECMal-PROTAC) of Example 1 in vivo.

[0222] The in vivo pharmacokinetic properties and biodistribution of ARV-771 and the cancer-targeting complex (ECMal-PROTAC) of Example 1 were investigated.

[0223] cancer animal models

[0224] Five-week-old female Balb / c and Balb / c nu / nu mice were purchased from NaraBio, Inc. (Seoul, Republic of Korea). Before the experiment, the mice underwent a two-week acclimatization period. Throughout the experiment, the mice were housed ad libitum in a breeding room maintained at 22 ± 2°C and 40–60% humidity, with a light-dark cycle of 12-h intervals. All experiments were conducted in compliance with the relevant laws and institutional guidelines of the KIST Institutional Animal Care and Use Committee (IACUC; Approval No. 2021-143).

[0225] 1 × 10 on the left thigh of the mouse 6 Inoculate 4T1 cells from the dog, and the tumor volume is 150-200 mm 3 Cancer animal models were produced by breeding them until they reached .

[0226] Preparation of samples

[0227] To analyze the in vivo therapeutic effect of the cancer-targeting complex (ECMal-PROTAC) of Example 1, samples were prepared as follows. A Cy5.5-BSA solution (Cy5.5-Alb, Preparation Example 1, 200 μM) diluted with PBS was mixed with the ECMal-PROTAC aqueous solution (140 μM) of Example 1 at a 1:1 volume ratio and co-incubated. The culture was allowed to react for 30 minutes under pH 8.0 conditions and then harvested to obtain Cy5.5-Alb-ECMal-PROTAC. Cy5.5-ARV-771 of Preparation Example 1 was used as a control.

[0228] Administration of the sample

[0229] To prepare the control and experimental groups, mice were randomly divided into groups of three each.

[0230] The control group used Cy5.5-ARV-771 (3 mg / kg, equiv. to ARV-771) as a sample, and the experimental group used Cy5.5-Alb-ECMal-PROTAC (3 mg / kg, equiv. to ARV-771) as a sample. The control group used saline (3 mg / kg) as a sample. Cy5.5-ARV-771 and Cy5.5-Alb-ECMal-PROTAC were administered via the tail vein.

[0231] analyze

[0232] To investigate temporal changes in blood circulation levels from each group, whole blood was collected at specific time points (0–96 hours). The collected blood samples were analyzed for fluorescence intensity using the IVIS Lumina Series III system, and the data were expressed as a function of time using GraphPad Prism 8 software to calculate blood half-life and the area under the curve (AUC).

[0233] Additionally, to analyze the degree of cancer accumulation, the control group and experimental group were administered samples and whole-body fluorescence images were taken using the IVIS Lumina Series Ⅲ system every 0, 1, 3, 6, 12, and 24 hours.

[0234] The control and experimental groups were euthanized 24 hours after administration, and major organs (heart, liver, lungs, spleen, and kidney) and cancer tissue were removed. Each extracted tissue was subjected to biodistribution and histological analysis, as follows.

[0235] To analyze the distribution of samples in the extracted cancer tissues, the extracted major organs and cancer tissues were photographed with an IVIS Lumina Series Ⅲ system (PerkinElmer, Waltham, MA, USA) and analyzed with Living Image software (PerkinElmer).

[0236] For histological analysis of the above-mentioned extracted cancer tissue, the isolated cancer tissue was immersed in a 4% formaldehyde solution, fixed at 4°C, and then cut into 1-2 mm 3 The sections were cut to the size of . Each section was incubated with shaking for 3 hours in TBST containing 3% BSA, and then stained by adding FITC-conjugated anti-CD31 primary antibody (Biolegend, USA) and incubating overnight at 4°C. Washed three times with TBST, placed on glass cover slides in DAPI mounting medium, and photographed using a confocal laser scanning microscope (CLSM; Leica TCS SP8, Leica Microsystems GmbH, Wetzlar, Germany). Quantification was performed using a microplate reader (VERSAmaxTM, Molecular Devices Corp., Sunnyvale, CA, USA) from the photographed images.

[0237] Results analysis

[0238] Figure 16 shows the pharmacokinetic profiles analyzing the plasma concentration according to the administration time in the comparative group (Cy5.5-ARV-771 intravenous administration) and the experimental group (Cy5.5-Alb-ECMal-PROTAC intravenous administration). According to this, it was confirmed that the blood half-life of the cancer-targeting complex (ECMal-PROTAC) of Example 1 was significantly increased in the case of Cy5.5-Alb-ECMal-PROTAC formed through binding to albumin. Specifically, as a result of observing the fluorescence intensity of Cy5.5-ARV-771 and Cy5.5-Alb-ECMal-PROTAC from the plasma of the comparative group and the experimental group, it was confirmed that Cy5.5-Alb-ECMal-PROTAC remained in the plasma for up to 12 hours, and Cy5.5-ARV-771 was completely removed after 1 hour. That is, it can be confirmed that the half-life of Cy5.5-Alb-ECMal-PROTAC is 0.59 hours, which is 3.5 times greater than that of Cy5.5-ARV-771. In addition, the AUC of Cy5.5-Alb-ECMal-PROTAC was confirmed to be 12 times greater than that of Cy5.5-ARV-771, indicating that the cancer-targeting complex (ECMal-PROTAC) according to the present invention has a significantly longer plasma retention time than conventional anticancer agents. The cancer-targeting complex (ECMal-PROTAC) according to the present invention improved the problems (hydrophobicity and low water solubility) of PROTAC molecules through in vivo albumin binding.

[0239] In graphs, including Figure 16, "hour" refers to time, a unit of time (period of time). Therefore, "1 hour" or "1 hour" is often used as "hour," meaning "60 minutes." However, in some specifications, "hour" and "time" may be used interchangeably, and in such cases, the meaning can be determined based on the context.

[0240]

[0241] Figure 17 is a non-invasive near-infrared fluorescence (NIRF) photograph of the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC) over time.

[0242] According to Figure 17, the experimental group (Cy5.5-Alb-ECMal-PROTAC intravenous administration) was specifically accumulated in cancer tissue, and it was confirmed that this was a significantly higher concentration than the comparative group (Cy5.5-ARV-771 intravenous administration).

[0243]

[0244] Figure 18 shows the results of quantifying only the fluorescence signal of cancer tissues from the comparison group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC) of Figure 17 (**** p < 0.0001). According to this, Cy5.5-Alb-ECMal-PROTAC was confirmed to reach the highest level 12 hours after administration. The fluorescence intensity of Cy5.5-Alb-ECMal-PROTAC was 12.6 times higher than that of Cy5.5-ARV-771.

[0245]

[0246] Figure 19 shows the ex vivo fluorescence images (a) and quantified fluorescence intensity graphs (b) of major organs (liver, lung, spleen, kidney, heart) and cancer tissues collected from the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC). Figure 20 shows the fluorescence images (top) and quantified fluorescence intensity graphs (bottom) of cancer tissues collected from the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC) (*** p < 0.001).

[0247] According to Figures 19 and 20, the control group administered with Cy5.5-ARV-771 was confirmed to have a very strong fluorescent signal in the kidney tissue and a very weak fluorescent signal in the cancer tissue and other organ tissues, indicating that a significant portion of Cy5.5-ARV-771 was immediately eliminated through the kidney.

[0248] On the other hand, the experimental group administered Cy5.5-Alb-ECMal-PROTAC showed strong fluorescence signals in liver tissue and cancer tissue, and in particular, the fluorescence intensity of cancer tissue was confirmed to be 16.3 times higher than that of Cy5.5-ARV-771. In other words, the cancer-targeting complex (ECMal-PROTAC) according to the present invention not only has a longer retention time in the body compared to conventional PROTACs, but also has high stability, making it very unlikely to induce renal excretion, and also has excellent cancer tissue targeting ability.

[0249]

[0250] Figure 21 is an enlarged fluorescence image of cancer tissues extracted from the control group (intravenous administration of Cy5.5-ARV-771) and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC).

[0251] According to Fig. 21, it was confirmed that the cancer tissue of the experimental group had a large amount of Cy5.5-Alb-ECMal-PROTAC distributed evenly throughout the entire tissue. On the other hand, it was confirmed that Cy5.5-ARV-771 was not distributed evenly throughout the cancer tissue of the comparative group, and in particular, fluorescence was hardly observed inside the cancer tissue. In other words, it can be seen that the cancer-targeting complex (ECMal-PROTAC) according to the present invention sufficiently penetrates a large amount into the central tissue of the cancer and induces an anticancer effect throughout the cancer tissue. Conventional anticancer drugs cannot deliver their effects to the interior of dense cancer tissues, and thus require excessive doses or excessive treatment periods for complete killing and treatment of cancer. However, the cancer-targeting complex (ECMal-PROTAC) according to the present invention is easily delivered to the center of the cancer tissue even when the same dose is used, and thus can achieve a remarkable pharmacological effect that is not predictable compared to conventional anticancer drugs.

[0252]

[0253] Figure 22 is an image taken with a confocal laser scanning microscope after staining cancer tissues extracted from the control group (Cy5.5-ARV-771 intravenous administration) and the experimental group (Cy5.5-Alb-ECMal-PROTAC intravenous administration) with DAPI and CD31 markers, and Figure 23 is an image taken with a confocal laser scanning microscope after staining cancer tissues from the control group (Saline, control) that was administered saline instead of a sample with DAPI and CD31 markers.

[0254] According to Figures 22 and 23, the cancer tissues of the experimental group administered with Cy5.5-Alb-ECMal-PROTAC showed that a greater amount of Cy5.5-Alb-ECMal-PROTAC was delivered to the cancer, and that the delivered drugs completely penetrated not only the cancer tissues surrounding blood vessels but also the cancer tissues inside the blood vessels. In addition, it was confirmed that a large amount of Cy5.5-Alb-ECMal-PROTAC was absorbed and accumulated inside the cells.

[0255] That is, it can be seen that the cancer targeting complex (ECMal-PROTAC) according to the present invention is delivered deep into cells not only surrounding blood vessels but also inside cancer tissues, and thus exhibits an unexpectedly significant anticancer effect that could not be obtained from conventional anticancer agents.

[0256]

[0257] Figure 24 is a graph depicting the fluorescence signal of cross-sections of cancer tissues extracted from the control group (control, saline), the comparative group (intravenous administration of Cy5.5-ARV-771), and the experimental group (intravenous administration of Cy5.5-Alb-ECMal-PROTAC).

[0258] According to Figure 24, the cancer tissues of the experimental group showed a significant difference between Cy5.5 and CD31 signals, while no significant difference was observed between Cy5.5 and CD31 signals in the cancer tissues of the control and comparative groups. In other words, it was confirmed that the cancer-targeting complex (ECMal-PROTAC) according to the present invention has a long blood retention time, accumulates specifically in cancer tissues, and the drug penetrates widely and uniformly into cancer tissues in addition to vascular tissues. This is a significant and remarkable difference compared to conventional anticancer agents.

[0259]

[0260] Experimental Example 9. Analysis of the anticancer efficacy of a cancer-targeting complex (ECMal-PROTAC) in an animal cancer model.

[0261] The in vivo cancer therapeutic efficacy of ARV-771 and the cancer targeting complex (ECMal-PROTAC) of Example 1 was investigated.

[0262] cancer animal models

[0263] Five-week-old female Balb / c and Balb / c nu / nu mice were purchased from NaraBio, Inc. (Seoul, Republic of Korea). Before the experiment, the mice underwent a two-week acclimatization period. Throughout the experiment, the mice were housed ad libitum in a breeding room maintained at 22 ± 2°C and 40–60% humidity, with a light-dark cycle of 12-h intervals. All experiments were conducted in compliance with the relevant laws and institutional guidelines of the KIST Institutional Animal Care and Use Committee (IACUC; Approval No. 2021-143).

[0264] 1 × 10 on the left thigh of the mouse 6 Inoculate 4T1 cells from the dog, and the tumor volume is 50-80 mm 3 Cancer animal models were produced by breeding them until they reached .

[0265] Administration of the sample

[0266] To prepare the control group, comparison group, and experimental group, mice were randomly divided into groups of 5 each.

[0267] The control group was administered 10 mg / kg of saline via the tail vein once every 3 days for 15 days (a total of 4 administrations). The comparison group was administered 10 mg / kg of ARV-771 via the tail vein once every 3 days for 15 days (a total of 4 administrations). The experimental group was administered 10 mg / kg (wquiv. to ARV-771) of ECMal-PROTAC of Example 1 via the tail vein once every 3 days for 15 days (a total of 4 administrations).

[0268] analyze

[0269] The size and weight of tumors were measured once every two days from the control, comparison, and experimental groups.

[0270] After 15 days, the control, comparison, and experimental groups were euthanized and major organs (heart, liver, lungs, spleen, and kidneys) and cancer tissues were removed.

[0271] To confirm whether the cancer targeting complex (ECMal-PROTAC) of Example 1 exhibits cancer-specific BRD4 degradation activity in vivo, cancer tissues were extracted from the control group, comparative group, and experimental group, and BRD4-related gene expression was analyzed using Western blot.

[0272] Additionally, to analyze cancer cell apoptosis, a TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay was performed on cancer tissues extracted from the control, comparative, and experimental groups. Next, the major organ tissues and cancer tissues extracted from each group were stained with H&E (hematoxylin & eosin) and subjected to histological analysis.

[0273] Analysis results

[0274] Figure 25 is a graph showing the tumor size measured from the control group, comparison group, and experimental group over time (if there is no significant difference, it is indicated as ns. **** p < 0.0001).

[0275] According to Fig. 25, it was confirmed that the tumor size of the experimental group administered the cancer targeting complex (ECMal-PROTAC) of Example 1 was significantly reduced. The control group and the comparison group showed an increase in the tumor size by 15.8 times and 14.8 times from day 0, respectively, and it was confirmed that there was no significant difference between the two groups. On the other hand, the experimental group administered the cancer targeting complex (ECMal-PROTAC) of Example 1 showed a significant decrease in the increase in tumor size. In the experimental group administered the cancer targeting complex (ECMal-PROTAC) of Example 1, the tumor volume was 176.13 ± 81.62 mm 15 days after administration. 3 It was confirmed that this was 6.1 times and 5.3 times smaller than the control group and comparison group, respectively.

[0276] ARV-771 and ECMal-PROTAC showed similar levels of toxicity against cancer cells in in vitro experiments, but in vivo, ECMal-PROTAC was confirmed to have antitumor efficacy 5-6 times higher than ARV-771.

[0277]

[0278] Figure 26 is an optical image of cancer tissues extracted from the control, comparison, and experimental groups. Figure 27 is a confocal laser scanning image taken after TUNEL staining of cancer tissues extracted from the control, comparison, and experimental groups.

[0279] According to Figures 26 and 27, it can be confirmed that the experimental group administered the cancer-targeting complex (ECMal-PROTAC) of Example 1 had a much smaller cancer size than the other groups. In addition, it was confirmed that the experimental group administered the cancer-targeting complex (ECMal-PROTAC) of Example 1 induced apoptosis of cancer cells throughout the cancer tissue.

[0280]

[0281] Figure 28 is a graph showing the analysis of body weight changes in the control group, comparison group, and experimental group. According to this, neither the experimental group nor the comparison group administered the cancer-targeting complex (ECMal-PROTAC) or ARV-771 of Example 1 exhibited serious systemic side effects, and no significant weight loss was observed. In other words, it can be seen that the cancer-targeting complex (ECMal-PROTAC) of Example 1 and ARV-771 are safe substances that do not cause side effects in vivo.

[0282]

[0283] Figure 29 shows the results of histological analysis of organ tissues (liver, lung, spleen, kidney, heart) and cancer tissues extracted from the control group, comparative group, and experimental group.

[0284] According to Fig. 29, after 15 days from the control group, comparative group, and experimental group, major organ tissues and cancer tissues were extracted. The extracted organ tissues and cancer tissues were stained with H&E (hematoxylin & eosin), and the H&E-stained tissues were observed using a BX51 optical microscope (Olympus, Tokyo, Japan) and a TCS SP8 confocal laser microscope.

[0285] According to Figure 29, severe damage was observed in the cancer tissues of the experimental group treated with the cancer-targeting complex (ECMal-PROTAC) of Example 1, while no significant damage was observed in organ tissues other than the cancer tissues. In the comparative group administered ARV-771, no serious damage was observed in either the cancer tissues or organ tissues. In other words, it was confirmed that administration of ARV-771 did not harm normal tissues, but did not harm cancer tissues either (anticancer efficacy was poor).

[0286] What is particularly noteworthy is that, although in the previous biodistribution experiment, it was confirmed that a significant portion of the cancer-targeting complex (ECMal-PROTAC) of Example 1 was delivered to liver tissue as well as cancer tissue, the cancer-targeting complex (ECMal-PROTAC) of Example 1 did not cause damage to liver tissue. In other words, it can be seen that the cancer-targeting complex (ECMal-PROTAC) of Example 1 does not cause cell death except in cancer tissue even if it accumulates in normal tissue, and causes damage and cell death specifically only in cancer tissue.

[0287]

[0288] Figure 30 shows the results of TUNEL analysis on liver tissues extracted from the control, comparative, and experimental groups.

[0289] According to Figure 30, no significant difference in cell death rate was observed in the liver tissues extracted from the experimental group compared to the liver tissues of the control group. These results indicate that the cancer-targeting complex (ECMal-PROTAC) of Example 1 accumulates in large concentrations in liver tissues when administered in vivo, but exhibits little toxicity to normal cells and exhibits specific activity only against cancer cells.

[0290] When ARV-771 was treated alone (control group), it was confirmed to have an effect on both normal and cancerous tissues.

[0291]

[0292] Figure 31 shows the results of analyzing the expression levels of BRD4, c-Myc, and Bcl-2 in cancer tissues extracted from the control, comparative, and experimental groups using Western blot. Figure 32 is a graph showing the quantification of the results of Figure 31 (** p < 0.01, **** p < 0.0001).

[0293] According to Fig. 31, the cancer tissues of the experimental group administered with the cancer targeting complex (ECMal-PROTAC) of Example 1 were confirmed to have significantly lower levels of BRD4, c-Myc, and Bcl-2 than the cancer tissues of the control group. On the other hand, no significant difference was observed in the levels of BRD4, c-Myc, and Bcl-2 between the cancer tissues of the experimental group administered with the cancer targeting complex (ECMal-PROTAC) of Example 1 and the cancer tissues of the comparison group.

[0294] According to Figure 32, the relative expression levels of BRD4, c-Myc, and Bcl-2 in the cancer tissues of the experimental group administered with the cancer targeting complex (ECMal-PROTAC) of Example 1 were confirmed to be 7.5 times, 2.2 times, and 2.3 times lower, respectively, than those of the control group.

[0295]

[0296] Figure 33 is a photograph taken using a confocal laser scanning microscope of cancer tissues extracted from the control group (Control, Saline), the comparative group (ARV-771, intravenous administration), and the experimental group (ECMal-PROTAC, intravenous administration), after staining with DAPI, anti-BRD4, and anti-c-Myc.

[0297] According to Figure 33, the experimental group treated with the cancer-targeting complex (ECMal-PROTAC) of Example 1 showed weaker fluorescence signals related to c-Myc and BRD4 compared to the comparison group and the control group. In the cancer tissue of the comparison group administered with ARV-771, it was confirmed that BRD4 degradation was not sufficient to induce cell death in the cancer tissue, indicating that the comparison group did not exhibit sufficient anticancer effects.

[0298]

[0299] Figure 34 shows the results of staining cancer tissues extracted from the control group, comparative group, and experimental group with DAB, and according to this, it was confirmed that BRD4 deficiency was observed in the cancer tissues of the experimental group administered the cancer targeting complex (ECMal-PROTAC) of Example 1.

[0300] That is, it was confirmed that the cancer-targeting complex (ECMal-PROTAC) of Example 1 successfully decomposes and reduces BRD4 in cancer tissues in vivo. The general mechanism of BRD4 deficiency-related cancer cell death is shown in Figure 35.

[0301] The cancer cell death process associated with BRD4 deficiency is as follows. c-Myc protein plays an important role in the growth and proliferation of cancer cells, and Bcl-2 induces an apoptosis inhibitory effect. Therefore, when BRD4 degradation is induced in cancer tissues, BRD4 becomes deficient, efficiently suppressing the production of c-Myc and Bcl-2 in cancer cells, resulting in cell death. The cancer-targeting complex (ECMal-PROTAC) of Example 1, when administered in vivo, forms an in situ bond with plasma albumin present in blood vessels, thereby exhibiting low systemic toxicity but high specificity for cancer, and not only has a high absorption rate in cancer cells, but also penetrates widely and deeply into the central part of cancer tissues, and induces apoptosis by suppressing the production of c-Myc and Bcl-2 proteins through the BRD4 degradation pathway in cancer cells, thereby inhibiting the proliferation of cancer cells and inducing apoptosis, thereby exhibiting an anticancer effect.

Claims

1. (i) maleimide functional group; (ii) a linker cleavable by an esterase linked to the functional group; and (iii) a cancer targeting complex comprising a PROTAC connected to the linker; The linker is at least one non-peptide linker selected from the group consisting of a peptide linker comprising one or more amino acid sequences selected from the group consisting of G, GG and GGG, PABC (p-aminocarbamate), MBA (N,N'-mythylenebisacrylamide), alkylene linker, arylene linker, polyalkylene oxide linker (e.g., PEG), NHS ester linker, Triazene linker, hydrazone linker, disulfide linker, glucuronide-MABC linker, YSZ linker and dialkoxydiphenylsilane linker, or a linker in the form of a mixture of the peptide linker and the non-peptide linker. A cancer targeting complex characterized in that the above Y is an azide (N3), an alkyl azide (-R'-N=N=N) having 1 to 6 carbon atoms, the above Z is any one selected from tetrazine, trans-cyclooctene, and cyclooctene, and the above S is any one selected from oligo or poly(ethylene glycol) (PEG), dextran, and an alkyl having 1 to 10 carbon atoms.

2. In paragraph 1, 상기 프로탁(PROTAC)은 CDK9(Cyclin-dependent kinase 9) / CDK family, BRD4(Bromodomain-containing protein 4) / BET(Bromodomain and extra-terminal) family, SHP-2(Src homology region 2 domain-containing phosphatase-2), AR(Androgen receptor), ER(Estrogen receptor), RAR(Retinoic acid receptor), ERRα(Estrogen-related receptor alpha), BTK(Bruton's tyrosine kinase), ALK(Anaplastic lymphoma kinase), RIPK(Receptor-interacting serine / threonine-protein kinase), c-Met(MET proto-oncogene / receptor tyrosine kinase), FAK(Focal adhesion kinase), IRAK4(Interleukin-1 receptor-associated kinase 4), p38 MAPK(p38 mitogen-activated protein kinases), SGK(Serum and glucocorticoid-regulated kinase), TBK1(TANK-binding kinase 1), KRAS(Kirsten rat sarcoma virus protein), B-Raf(B-Raf proto-oncogene serine / threonine kinase), β-catenin, FKBP(FK506 binding protein), IDO(Indoleamine 2,3-dioxygenase), PD-1 / PD-L1(Programmed death protein 1 / programmed death-ligand 1), PARP1(Poly [ADP-ribose] polymerase 1),PRC2 (Polycomb repressive complex 2), EGFR (Epidermal growth factor receptor), Sirt2 (NAD-dependent deacetylase sirtuin 2), HER2 / ERBB2 (Human epidermal growth factor receptor 2), FRS2 (Fibroblast growth factor receptor substrate 2), BCL-XL (B-cell lymphoma-extra large), SMARCA (SWI / SNF related matrix associated actin dependent regulator of chromatin subfamily A), HDM2 (Human double minute 2 homolog), HDAC (Histone deacetylase) family, BCR-ABL (Breakpoint cluster region protein- Tyrosine-protein kinase ABL1), MCL1 (Modulator Of VRAC Current 1), FLT-3 (Fms Related Receptor Tyrosine Kinase 3), STAT3 (Transcription factor STAT3), Myc family and BAF. At least one selected from the group consisting of complex (Brg / Brahma-associated factors) A cancer-targeting complex characterized by targeting proteins.

3. In paragraph 1, A cancer targeting complex characterized in that the linker is YSZ (Y is an azide (N3) group or an alkylazide (-R'-N=N=N, where R' is an alkyl group having 1 to 6 carbon atoms) having 1 to 6 carbon atoms, Z is trans-cyclooctene or cyclooctene, and S is poly(ethylene glycol)), or a linker in the form of a mixture of a peptide linker composed of 1 to 3 glycines (G) and a non-peptide linker of poly(ethylene glycol).

4. In paragraph 1, A cancer-targeting complex characterized in that the cancer-targeting anticancer agent is represented by the following chemical formula 1 or 2. [Chemical Formula 1] [Chemical Formula 2] 5. In paragraph 1, The above cancer targeting complex is characterized in that it binds to albumin present in a living body and is formed in a stabilized and inactivated form.

6. In paragraph 1, The above cancer targeting complex is characterized in that it penetrates into cancer cells and is cleaved by esterase present in the cancer cells to release PROTAC.

7. A pharmaceutical composition for preventing or treating cancer, comprising a cancer targeting complex according to Article 1 as an active ingredient.

8. In paragraph 7, A pharmaceutical composition for preventing or treating cancer, characterized in that the cancer targeting complex is formed in a stabilized and inactivated form by binding to albumin existing in a living body.

9. In paragraph 7, A pharmaceutical composition for preventing or treating cancer, characterized in that the cancer is at least one selected from brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, duodenal cancer, appendix cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anal cancer, renal cancer, ureteral cancer, bladder cancer, prostate cancer, penile cancer, testicular cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer, and skin cancer.

10. A food composition for preventing or improving cancer, comprising a cancer-targeting complex according to Article 1 as an active ingredient.

Citation Information

Patent Citations

  • Image sensor device, rollable display device and driving method

    KR1020230057607A

  • Compounds and methods for suppressing an immune response to substances containing polyethylene glycol

    WO2021234676A1